AZP-40XX: Primary Hyperparathyroidism (PHPT) and Humoral Hypercalcemia of Malignancy (HHM)

AZP-40XX is a select group of monoclonal antibodies targeting the parathyroid receptor 1 (PTHR1) that are undergoing preclinical evaluation as potential treatments for PHPT and HHM. The objective of the evaluation is to select a candidate antibody for development that can lessen the symptoms and serious complications of these conditions.

The AZP-40XX series arose from XOMA’s legacy discovery efforts and is being optimized through a research agreement and licensing option, and represents a natural expansion of Amolyt’s pipeline.